Maykov, E B <br/><br/>
[Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter].  [electronic resource] 

 -  Terapevticheskii arkhiv  2015 
 - 38-48 p.  digital 
<br/><br/> Publication Type: Clinical Trial; English Abstract; Journal Article 
<br/><br/><label>ISSN: </label>0040-3660 
<br/><br/><label>Standard No.: </label>10.17116/terarkh201587138-48  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Action Potentials--drug effects<br/>Anti-Arrhythmia Agents--administration & dosage<br/>Atrial Fibrillation--drug therapy<br/>Atrial Flutter--drug therapy<br/>Data Interpretation, Statistical<br/>Dose-Response Relationship, Drug<br/>Echocardiography<br/>Electrocardiography, Ambulatory<br/>Female<br/>Heart--drug effects<br/>Humans<br/>Male<br/>Middle Aged<br/>Piperidines--administration & dosage<br/>Potassium Channels--metabolism<br/>Treatment Outcome